Experimental autoimmune encephalomyelitis as a testing paradigm for adjuvants and vaccines

Vaccine

Volumn 29, Issue 17, 2011, Pages 3356-3362

  Libbey, Jane E ^a   Fujinami, Robert S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Experimental Autoimmune Encephalomyelitis; Vaccination

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MONTANIDE ISA 51; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PLASMID DNA; PROTEOLIPID PROTEIN; VACCINE; VIRUS DNA;

ALLERGIC ENCEPHALOMYELITIS; BORDETELLA PERTUSSIS; CPG ISLAND; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DNA IMMUNIZATION; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; HUMAN; IMMUNOMODULATION; INOCULATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULAR MIMICRY; MOUSE STRAIN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINIA VIRUS; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; VACCINATION; VACCINES, DNA; VIRAL VACCINES;

EID: 79954575661     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.103     Document Type: Review

References (62)

1. Tsunoda I., Fujinami R.S. Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J Neuropathol Exp Neurol 1996, 55:673-686.
2. Freund J., McDermott K. Sensitization to horse serum by means of adjuvants. Proc Soc Exp Biol Med 1942, 49:548-553.
3. Sedzik J. Myelin sheaths and autoimmune response induced by myelin proteins and alphaviruses. I. Physicochemical background. Curr Med Chem 2008, 15:1899-1910.
4. Fritz R.B., Chou C-H.J., McFarlin D.E. Relapsing murine experimental allergic encephalomyelitis induced by myelin basic protein. J Immunol 1983, 130:1024-1026.
5. Satoh J., Sakai K., Endoh M., Koike F., Kunishita T., Namikawa T., et al. Experimental allergic encephalomyelitis mediated by murine encephalitogenic T cell lines specific for myelin proteolipid apoprotein. J Immunol 1987, 138:179-184.
6. S mouse strains. Brain Pathol 2000, 10:402-418.
7. Tsunoda I., Libbey J.E., Kuang L.-Q., Terry E.J., Fujinami R.S. Massive apoptosis in lymphoid organs in animal models for primary and secondary progressive multiple sclerosis. Am J Pathol 2005, 167:1631-1646.
8. Pohl-Koppe A., Burchett S.K., Thiele E.A., Hafler D.A. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol 1998, 91:19-27.
9. Fujinami R.S. Can virus infections trigger autoimmune disease?. J Autoimmun 2001, 16:229-234.
10. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology 2010, epub ahead of print.
11. Mix E., Meyer-Rienecker H., Hartung H.P., Zettl U.K. Animal models of multiple sclerosis-potentials and limitations. Prog Neurobiol 2010, epub ahead of print.
12. Johnson A.J., Suidan G.L., McDole J., Pirko I. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?. Int Rev Neurobiol 2007, 79:73-97.
13. + T cells in multiple sclerosis and its animal models. Curr Drug Targets Inflamm Allergy 2005, 4:239-245.
14. + T cells in a model for multiple sclerosis. J Exp Med 2001, 194:669-676.
15. + T cells. Ann N Y Acad Sci 2007, 1103:157-166.
16. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol 2007, 17:219-229.
17. + T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001, 166:7579-7587.
18. Pöllinger B., Krishnamoorthy G., Berer K., Lassmann H., Bösl M.R., Dunn R., et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med 2009, 206:1303-1316.
19. Gran B., Zhang G.-X., Yu S., Li J., Chen X.-H., Ventura E.S., et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002, 169:7104-7110.
20. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
21. Aranami T., Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008, 57:115-120.
22. Klemann C., Je Raveney B., Oki S., Yamamura T. Retinoid signals and Th17-mediated pathology. Jpn J Clin Immunol 2009, 32:20-28.
23. Veldhoen M., Hocking R.J., Flavell R.A., Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006, 7:1151-1156.
24. + T cells. Proc Natl Acad Sci USA 2009, 106:876-881.
25. Hofstetter H.H., Toyka K.V., Tary-Lehmann M., Lehmann P.V. Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol 2007, 178:1372-1378.
26. Xie L., Li X.-K., Funeshima-Fuji N., Kimura H., Matsumoto Y., Isaka Y., et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009, 9:575-581.
27. Barnett L.A., Whitton J.L., Wada Y., Fujinami R.S. Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein [published erratum appears in J Neuroimmunol 48:120, 1993]. J Neuroimmunol 1993, 44:15-25.
28. Libbey JE, Fujinami RS. Potential triggers of MS in: R Martin and A Lutterotti (Eds.), Molecular Basis of Multiple Sclerosis. The Immune System, in: Results and Problems in Cell Differentiation, vol. 51, Springer, New York, Berlin & Heidelberg, 2010, pp. 21-42.
29. Barnett L.A., Whitton J.L., Wang L.Y., Fujinami R.S. Virus encoding an encephalitogenic peptide protects mice from experimental allergic encephalomyelitis. J Neuroimmunol 1996, 64:163-173.
30. Genain C.P., Gritz L., Joshi N., Panicali D., Davis R.L., Whitaker J.N., et al. Inhibition of allergic encephalomyelitis in marmosets by vaccination with recombinant vaccinia virus encoding for myelin basic protein. J Neuroimmunol 1997, 79:119-128.
31. Zamvil S.S., Mitchell D.J., Moore A.C., Kitamura K., Steinman L., Rothbard J.B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986, 324:258-260.
32. Fritz R.B., McFarlin D.E. Encephalitogenic epitopes of myelin basic protein. Chem Immunol 1989, 46:101-125.
33. Sobel R.A., Greer J.M., Kuchroo V.K. Minireview: autoimmune responses to myelin proteolipid protein. Neurochem Res 1994, 19:915-921.
34. Tuohy V.K. Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review. Neurochem Res 1994, 19:935-944.
35. Wang L.-Y., Fujinami R.S. Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol 1997, 75:75-83.
36. Wang L.-Y., Theil D.J., Whitton J.L., Fujinami R.S. Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing-remitting experimental allergic encephalomyelitis. J Neuroimmunol 1999, 96:148-157.
37. Theil D.J., Tsunoda I., Rodriguez F., Whitton J.L., Fujinami R.S. Viruses can silently prime for and trigger central nervous system autoimmune disease. J NeuroVirol 2001, 7:220-227.
38. Tsunoda I., Libbey J.E., Fujinami R.S. Sequential polymicrobial infections lead to CNS inflammatory disease: possible involvement of bystander activation in heterologous immunity. J Neuroimmunol 2007, 188:22-33.
39. McCoy L., Tsunoda I., Fujinami R.S. Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 2006, 39:9-19.
40. Willenborg D.O., Fordham S.A., Cowden W.B., Ramshaw I.A. Cytokines and murine autoimmune encephalomyelitis: inhibition or enhancement of disease with antibodies to select cytokines, or by delivery of exogenous cytokines using a recombinant vaccinia virus system. Scand J Immunol 1995, 41:31-41.
41. Tsunoda I., Kuang L.-Q., Tolley N.D., Whitton J.L., Fujinami R.S. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J Neuropathol Exp Neurol 1998, 57:758-767.
42. Ruiz P.J., Garren H., Ruiz I.U., Hirschberg D.L., Nguyen L-VT, Karpuj M.V., et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J Immunol 1999, 162:3336-3341.
43. Garren H., Ruiz P.J., Watkins T.A., Fontoura P., Nguyen L-VT, Estline E.R., et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 2001, 15:15-22.
44. Kim S.-K., Cornberg M., Wang X.Z., Chen H.D., Selin L.K., Welsh R.M. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J Exp Med 2005, 201:523-533.
45. Selin L.K., Cornberg M., Brehm M.A., Kim S.K., Calcagno C., Ghersi D., et al. CD8 memory T cells: cross-reactivity and heterologous immunity. Semin Immunol 2004, 16:335-347.
46. + T-cell cross-reactivity and heterologous immunity. Immunol Rev 2006, 211:164-181.
47. Welsh R.M., Kim S.K., Cornberg M., Clute S.C., Selin L.K., Naumov Y.N. The privacy of T cell memory to viruses. Curr Top Microbiol Immunol 2006, 311:117-153.
48. Theil D.J., Libbey J.E., Rodriguez F., Whitton J.L., Tsunoda I., Derfuss T.J., et al. Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis. J Neuroimmunol 2008, 204:92-100.
49. Andreasen C., Powell D.A., Carbonetti N.H. Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice. PLoS ONE 2009, 4:e7079.
50. Higgins S.C., Jarnicki A.G., Lavelle E.C., Mills K.H.G. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006, 177:7980-7989.
51. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18:1217-1225.
52. Tsunoda I., Tolley N.D., Theil D.J., Whitton J.L., Kobayashi H., Fujinami R.S. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol 1999, 9:481-493.
53. Tigno-Aranjuez J.T., Jaini R., Tuohy V.K., Lehmann P.V., Tary-Lehmann M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J Immunol 2009, 183:5654-5661.
54. Whitton J.L., Fujinami R.S. Viruses as triggers of autoimmunity: facts and fantasies. Curr Opin Microbiol 1999, 2:392-397.
55. von Herrath M.G., Fujinami R.S., Whitton J.L. Microorganisms and autoimmunity: making the barren field fertile?. Nat Rev Microbiol 2003, 1:151-157.
56. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32:155-172.
57. Tagliabue A., Rappuoli R. Vaccine adjuvants. The dream becomes real. Hum Vaccin 2008, 4:347-349.
58. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314:1936-1938.
59. Ishii K.J., Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 2007, 27:363-371.
60. Klinman D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006, 25:135-154.
61. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003, 2:727-735.
62. Aucouturier J., Ascarateil S., Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006, 24(Suppl. 2):S2-S5.